↓ Skip to main content

Cochrane Database of Systematic Reviews

Intravenous immunoglobulin for Guillain-Barré syndrome.

Overview of attention for article published in Cochrane database of systematic reviews, July 2012
Altmetric Badge

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
109 Dimensions

Readers on

mendeley
74 Mendeley
Title
Intravenous immunoglobulin for Guillain-Barré syndrome.
Published in
Cochrane database of systematic reviews, July 2012
DOI 10.1002/14651858.cd002063.pub5
Pubmed ID
Authors

Hughes RA, Swan AV, van Doorn PA

Abstract

Guillain-Barré syndrome (GBS) is an acute, paralysing, inflammatory peripheral nerve disease. Intravenous immunoglobulin (IVIg) is beneficial in other autoimmune diseases. This is an update of a review first published in 2001 and previously updated in 2003, 2005, 2007 and 2010. Other Cochrane systematic reviews have shown that plasma exchange (PE) significantly hastens recovery in GBS compared with supportive treatment alone, and that corticosteroids alone are ineffective.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 3%
Unknown 72 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 11 15%
Researcher 9 12%
Student > Master 8 11%
Other 7 9%
Student > Postgraduate 6 8%
Other 15 20%
Unknown 18 24%
Readers by discipline Count As %
Medicine and Dentistry 28 38%
Biochemistry, Genetics and Molecular Biology 4 5%
Agricultural and Biological Sciences 4 5%
Engineering 4 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Other 13 18%
Unknown 18 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 August 2012.
All research outputs
#17,662,702
of 22,673,450 outputs
Outputs from Cochrane database of systematic reviews
#11,263
of 12,297 outputs
Outputs of similar age
#122,009
of 164,336 outputs
Outputs of similar age from Cochrane database of systematic reviews
#148
of 171 outputs
Altmetric has tracked 22,673,450 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,297 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.3. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,336 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 171 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.